Permanent CEO. Helius has named interim CEO and President Dane Andreeff as full-time CEO and President. Mr. Andreeff was appointed to the interim roles in August 2020. Since assuming the roles, Mr. Andreeff guided Helius to FDA approval of the PoNS treatment for MS in the U.S. and is positioning the Company to capitalize on its key technology. Mr. Andreeff remains a significant owner of Helius with approximately 5% of the outstanding shares through his Maple Leaf Partners fund.New CFO. In addition, the Board appointed Jeffrey Mathiesen as CFO. Mr. Mathiesen served as a member of Helius' Board from June 2020 until June 2021. A CPA with over 30 years experience, Mr. Mathiesen brings a solid background as CFO for a number of growth oriented, technology-based companies across a wide range of industries, including biopharmaceutical and medical device companies. Our View. We are not surprised by the permanent appointment of Mr. Andreeff, given the positive momentum of the Company under his guidance. We believe Mr. Andreeff, with his financial, business, and strategic background is a great fit for Helius. The appointment of Mr. Mathiesen reflects the need of a growing company to "spread the opportunity" at a Company where many employees wear "two hats." We believe Mr. Mathiesen's background dovetails nicely with Helius. Former CFO Joyce LaViscount will continue in her role as Chief Operating Officer of Helius.Maintaining Outperform Rating. We are maintaining our Outperform rating and $20.00 12-month price target on HSDT shares. Through its PoNS device and treatment program, we believe Helius has a first mover advantage in using the tongue for neurostimulation to reduce symptoms of neurological disease or trauma. Read More >>